Silybin inhibits interleukin-1β-induced production of pro-inflammatory mediators in canine hepatocyte cultures

A. Y. Au, J. M. Hasenwinkel, C. G. Frondoza

Research output: Contribution to journalArticle

Abstract

Hepatocytes are highly susceptible to cytokine stimulation and are fundamental to liver function. We established primary canine hepatocyte cultures to study effects of anti-inflammatory agents with hepatoprotective properties. Hepatocyte cultures were incubated with control media alone, silybin (SB), or the more bioavailable silybin-phosphatidylcholine complex (SPC), followed by activation with interleukin-1 beta (IL-1β; 10ng/mL). Inflammatory response was measured by prostaglandin E2 (PGE 2), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) production and also nuclear factor-kappa B (NF-κB) translocation. Hepatocyte cultures continued production of the phenotypic marker albumin for more than 7days in culture. IL-1β exposure increased PGE 2, IL-8, and MCP-1 production, which was paralleled by NF-κB translocation from the cytoplasm to the nucleus. Pretreatment with SB and SPC significantly inhibited IL-1β-induced production of pro-inflammatory markers and attenuated NF-κB nuclear translocation. We demonstrate for the first time that primary canine hepatocyte cultures can be maintained in culture without phenotypic loss. The observation that hepatocyte cultures respond to pro-inflammatory IL-1β activation indicates hepatocytes as primary cellular targets of extrinsic IL-1β. The ability of SB and SPC to inhibit hepatocyte culture activation by IL-1β reinforces the notion of their hepatoprotective effects. Our primary canine hepatocyte culture model facilitates identification of hepatoprotective agents and their mechanism of action.

Original languageEnglish (US)
Pages (from-to)120-129
Number of pages10
JournalJournal of Veterinary Pharmacology and Therapeutics
Volume34
Issue number2
DOIs
StatePublished - Apr 2011

Fingerprint

interleukin-1
Interleukin-1
hepatocytes
Canidae
Hepatocytes
IdB 1016
dogs
NF-kappa B
phosphatidylcholines
hepatoprotective effect
Chemokine CCL2
interleukin-8
Interleukin-8
Dinoprostone
prostaglandins
anti-inflammatory agents
silybin
liver function
Interleukin-1beta
albumins

ASJC Scopus subject areas

  • Pharmacology
  • veterinary(all)

Cite this

Silybin inhibits interleukin-1β-induced production of pro-inflammatory mediators in canine hepatocyte cultures. / Au, A. Y.; Hasenwinkel, J. M.; Frondoza, C. G.

In: Journal of Veterinary Pharmacology and Therapeutics, Vol. 34, No. 2, 04.2011, p. 120-129.

Research output: Contribution to journalArticle

@article{6b5e090979f946c2ba927ba69361e98e,
title = "Silybin inhibits interleukin-1β-induced production of pro-inflammatory mediators in canine hepatocyte cultures",
abstract = "Hepatocytes are highly susceptible to cytokine stimulation and are fundamental to liver function. We established primary canine hepatocyte cultures to study effects of anti-inflammatory agents with hepatoprotective properties. Hepatocyte cultures were incubated with control media alone, silybin (SB), or the more bioavailable silybin-phosphatidylcholine complex (SPC), followed by activation with interleukin-1 beta (IL-1β; 10ng/mL). Inflammatory response was measured by prostaglandin E2 (PGE 2), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) production and also nuclear factor-kappa B (NF-κB) translocation. Hepatocyte cultures continued production of the phenotypic marker albumin for more than 7days in culture. IL-1β exposure increased PGE 2, IL-8, and MCP-1 production, which was paralleled by NF-κB translocation from the cytoplasm to the nucleus. Pretreatment with SB and SPC significantly inhibited IL-1β-induced production of pro-inflammatory markers and attenuated NF-κB nuclear translocation. We demonstrate for the first time that primary canine hepatocyte cultures can be maintained in culture without phenotypic loss. The observation that hepatocyte cultures respond to pro-inflammatory IL-1β activation indicates hepatocytes as primary cellular targets of extrinsic IL-1β. The ability of SB and SPC to inhibit hepatocyte culture activation by IL-1β reinforces the notion of their hepatoprotective effects. Our primary canine hepatocyte culture model facilitates identification of hepatoprotective agents and their mechanism of action.",
author = "Au, {A. Y.} and Hasenwinkel, {J. M.} and Frondoza, {C. G.}",
year = "2011",
month = "4",
doi = "10.1111/j.1365-2885.2010.01200.x",
language = "English (US)",
volume = "34",
pages = "120--129",
journal = "Journal of Veterinary Pharmacology and Therapeutics",
issn = "0140-7783",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Silybin inhibits interleukin-1β-induced production of pro-inflammatory mediators in canine hepatocyte cultures

AU - Au, A. Y.

AU - Hasenwinkel, J. M.

AU - Frondoza, C. G.

PY - 2011/4

Y1 - 2011/4

N2 - Hepatocytes are highly susceptible to cytokine stimulation and are fundamental to liver function. We established primary canine hepatocyte cultures to study effects of anti-inflammatory agents with hepatoprotective properties. Hepatocyte cultures were incubated with control media alone, silybin (SB), or the more bioavailable silybin-phosphatidylcholine complex (SPC), followed by activation with interleukin-1 beta (IL-1β; 10ng/mL). Inflammatory response was measured by prostaglandin E2 (PGE 2), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) production and also nuclear factor-kappa B (NF-κB) translocation. Hepatocyte cultures continued production of the phenotypic marker albumin for more than 7days in culture. IL-1β exposure increased PGE 2, IL-8, and MCP-1 production, which was paralleled by NF-κB translocation from the cytoplasm to the nucleus. Pretreatment with SB and SPC significantly inhibited IL-1β-induced production of pro-inflammatory markers and attenuated NF-κB nuclear translocation. We demonstrate for the first time that primary canine hepatocyte cultures can be maintained in culture without phenotypic loss. The observation that hepatocyte cultures respond to pro-inflammatory IL-1β activation indicates hepatocytes as primary cellular targets of extrinsic IL-1β. The ability of SB and SPC to inhibit hepatocyte culture activation by IL-1β reinforces the notion of their hepatoprotective effects. Our primary canine hepatocyte culture model facilitates identification of hepatoprotective agents and their mechanism of action.

AB - Hepatocytes are highly susceptible to cytokine stimulation and are fundamental to liver function. We established primary canine hepatocyte cultures to study effects of anti-inflammatory agents with hepatoprotective properties. Hepatocyte cultures were incubated with control media alone, silybin (SB), or the more bioavailable silybin-phosphatidylcholine complex (SPC), followed by activation with interleukin-1 beta (IL-1β; 10ng/mL). Inflammatory response was measured by prostaglandin E2 (PGE 2), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) production and also nuclear factor-kappa B (NF-κB) translocation. Hepatocyte cultures continued production of the phenotypic marker albumin for more than 7days in culture. IL-1β exposure increased PGE 2, IL-8, and MCP-1 production, which was paralleled by NF-κB translocation from the cytoplasm to the nucleus. Pretreatment with SB and SPC significantly inhibited IL-1β-induced production of pro-inflammatory markers and attenuated NF-κB nuclear translocation. We demonstrate for the first time that primary canine hepatocyte cultures can be maintained in culture without phenotypic loss. The observation that hepatocyte cultures respond to pro-inflammatory IL-1β activation indicates hepatocytes as primary cellular targets of extrinsic IL-1β. The ability of SB and SPC to inhibit hepatocyte culture activation by IL-1β reinforces the notion of their hepatoprotective effects. Our primary canine hepatocyte culture model facilitates identification of hepatoprotective agents and their mechanism of action.

UR - http://www.scopus.com/inward/record.url?scp=79952613343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952613343&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2885.2010.01200.x

DO - 10.1111/j.1365-2885.2010.01200.x

M3 - Article

C2 - 21395602

AN - SCOPUS:79952613343

VL - 34

SP - 120

EP - 129

JO - Journal of Veterinary Pharmacology and Therapeutics

JF - Journal of Veterinary Pharmacology and Therapeutics

SN - 0140-7783

IS - 2

ER -